STEPS TAKEN AFTER THE GRANTING MARKETING AUTHORIZATION  
For procedures finalised after 30 November 2004 please refer to module 8B. 
Subsequent post Marketing Authorisation applications agreed upon are summarised in the table below: 
Scope 
Application 
number 
Type of 
modification1 
Change in or addition of manufacturing site(s) for part or all 
of the manufacturing process 
Extension of indication in locally advanced or metastatic 
breast cancer 
Change in test procedure of active substance 
Batch size of active substance 
Minor changes in manufacture of the medicinal product 
Change in the batch size of finished product 
Minor change of manufacturing process of the active 
substance 
Update of Summary of Product Characteristics and Package 
Leaflet 
I/0002 
II/001 
I/003 
I/004 
I/005 
I/006 
I/007 
II/008 
I 
II 
I 
I 
I 
I 
I 
II 
Notification/ 
Opinion issued 
on2 
04.07.01 
Commission 
Decision 
Issued/amended 
on 
N/A 
26.02.03 
26.02.03 
26.02.03 
26.02.03 
26.02.03 
21.03.02 
11.03.03 
11.03.03 
11.03.03 
11.03.03 
11.03.03 
26.02.04 
25.03.04 
1 In accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended: I refers to a 
minor variation (Type I variation); II refers to a major variation (Type II variation); I/II refers to a minor 
variation following the procedure set out in Article 6, 7 and 8 of the Regulation; X refers to an Annex II 
application. 
T refers to a transfer of a Marketing Authorisation in accordance with Commission Regulation (EC) No 2141/96 
of 7 November 1996.  
N refers to a notification in accordance with Article 10(3) of Council Directive 92/27/EEC of 31 March 1992. 
2 For Notifications and Type I variations, the date of entry into force of the change is the EMEA Notification 
date. The Commission Decision will be amended accordingly. 
1/1 
   ï£©EMEA 2005 
 
 
 
 
 
 
 
 
 
 
 
 
                                                            
 
